Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.

PMID
30635338
Full Text

Wang, Xiaoli, Shuo Wang, Michael A. Morse, Ni Jiang, Yanjie Zhao, Yuguang Song, Lei Zhou, et al. “Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.” J Thromb Thrombolysis 47, no. 4 (May 2019): 505–11. https://doi.org/10.1007/s11239-019-01844-7.

PMID
30903459
Full Text

Liu, Seiya Y., Sant P. Chawla, Howard Bruckner, Michael A. Morse, Noah Federman, Jorge G. Ignacio, Filomena San Juan, Roseo A. Manalo, Frederick L. Hall, and Erlinda Maria Gordon. “Reporting Long Term Survival Following Precision Tumor-Targeted Gene Delivery to Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone.” In Molecular Therapy, 27:133–133. CELL PRESS, 2019.

Scholars@Duke

Chawla, Sant P., Howard Bruckner, Michael A. Morse, Nupur Assudani, Frederick L. Hall, and Erlinda M. Gordon. “A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.” Mol Ther Oncolytics 12 (March 29, 2019): 56–67. https://doi.org/10.1016/j.omto.2018.12.005.

PMID
30705966
Full Text

Fishman, M., J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, et al. “Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.” J Immunother Cancer 7, no. 1 (March 27, 2019): 84. https://doi.org/10.1186/s40425-019-0567-3.

PMID
30917871
Full Text

Qiao, Guoliang, Xiaoli Wang, Lei Zhou, Xinna Zhou, Yuguang Song, Shuo Wang, Lei Zhao, et al. “Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.” Clin Cancer Res 25, no. 5 (March 1, 2019): 1494–1504. https://doi.org/10.1158/1078-0432.CCR-18-2360.

PMID
30514775
Full Text

Crosby, E. J., W. R. Gwin, S. Chang, H. T. Maecker, V. Lubkov, J. C. Snyder, G. Broadwater, et al. “Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients.” In Poster Session Abstracts. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-p2-09-16.

Full Text

Wang, Jiangbo, Xiu-Rong Ren, Hailan Piao, Shengli Zhao, Takuya Osada, Richard T. Premont, Robert A. Mook, Michael A. Morse, Herbert Kim Lyerly, and Wei Chen. “Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.” Biochem J 476, no. 3 (February 8, 2019): 535–46. https://doi.org/10.1042/BCJ20180385.

PMID
30635359
Full Text

Morse, Michael A., Weijing Sun, Richard Kim, Aiwu Ruth He, Paolo B. Abada, Michelle Mynderse, and Richard S. Finn. “The Role of Angiogenesis in Hepatocellular Carcinoma.” Clin Cancer Res 25, no. 3 (February 1, 2019): 912–20. https://doi.org/10.1158/1078-0432.CCR-18-1254.

PMID
30274981
Full Text

Kane, Ari, Matthew P. Thorpe, Michael A. Morse, Brandon A. Howard, Jorge D. Oldan, Jason Zhu, Terence Z. Wong, Neil A. Petry, Robert Reiman, and Salvador Borges-Neto. “Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.” J Nucl Med 59, no. 11 (November 2018): 1708–13. https://doi.org/10.2967/jnumed.117.202150.

PMID
29777005
Full Text

Pages